3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia
33
Leukemia, Myeloid, Acute
31
Leukemia, Lymphocytic, Chronic, B-Cell
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Myelodysplastic Syndromes
18
Lymphoma, Non-Hodgkin
18
Lymphoma
17
Hodgkin Disease
16
Multiple Myeloma
12
Lymphoma, Mantle-Cell
11
Recurrence
10
Melanoma
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Follicular
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia, Myelomonocytic, Chronic
10
Burkitt Lymphoma
10
Waldenstrom Macroglobulinemia
8
Neoplasms, Plasma Cell
8
Neoplasm Metastasis
8
Myeloproliferative Disorders
8
Leukemia, Myeloid, Accelerated Phase
8
Lymphoma, Large-Cell, Immunoblastic
7
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia, Biphenotypic, Acute
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, B-Cell
6
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
4
pembrolizumab
3
aldesleukin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
Cyclophosphamide
2
Bevacizumab
2
veliparib
1
trametinib
1
spartalizumab
1
satraplatin
1
osimertinib
1
onartuzumab
1
nintedanib
1
methyl-4-fluoro-4-deoxyglucose
1
fludarabine phosphate
1
fludarabine
1
bemarituzumab
1
anlotinib
1
aflutinib
1
Taxes
1
Sorafenib
1
Sirolimus
1
Radiotherapy, Conformal
1
Radiosurgery
1
Pentostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma of Lung
×
fludarabine phosphate
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn